Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
회사 코드ILMN
회사 이름Illumina Inc
상장일Jun 28, 2000
설립일2000
CEOMr. Jacob Thaysen, Ph.D.
직원 수8970
유형Ordinary Share
회계 연도 종료Jun 28
주소5200 Illumina Way
도시SAN DIEGO
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호92122
전화18582024500
웹사이트https://www.illumina.com
회사 코드ILMN
상장일Jun 28, 2000
설립일2000
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음